30 March - 5 April 2019
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Mavenclad (cladribine) approved in USA
Mavenclad (cladribine) has been approved by the FDA, the US drug regulator, for relapsing forms of MS, including relapsing remitting MS and “active” secondary progressive MS. In the UK, Mavenclad has been approved as an NHS treatment since 2017.
MS Trust link: Mavenclad
Gabapentin and pregabalin reclassified
From April 1, gabapentin and pregabalin have been reclassified as controlled drugs. This has resulted in changes to how they are prescribed, particularly for repeat prescriptions.
MS Trust link: Gabapentin and pregabalin - new rules for prescriptions
MS in the Media
27 Nov 2020 - 00:00
- Depression affects multitasking in MS
- Benefits process in Scotland
- Cancer risks and multiple sclerosis
- Gut immune cells and relapses
MS in the Media
20 Nov 2020 - 00:00
- New study for advanced MS
- Campaign for fair benefits during the pandemic
- Stem cells compared to Lemtrada
- DMD use and finances
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.